Correlation of Serum Chromogranin A Change with Radiographic Response in Patients with Non-Functioning Advanced Neuroendocrine Tumors Abstract #826

Introduction: Numerous studies have suggested that CgA determination may be useful for the diagnosis and follow-up of neuroendocrine tumors (NETs).
Aim(s): To determine the sensitivity of CgA in diagnosis of non-functioning NETs, and the correlation of CgA change with radiographic response in patients with advanced non-functioning NETs.
Materials and methods: Serial CgA determinations were performed in 29 patients (24 pNETs, five others, 80 visits) with locally advanced (n=3) or metastatic (n=26) non-functioning NETs on various treatments. Changes in CgA levels over 25% were considered as significant. CT and/or MRI were performed at each visit for response determination using RECIST 1.1 criteria.
Conference: 11th Annual ENETS Conference (2014)
Category: Biomarkers
Presenting Author: Yuejuan Cheng

To read results and conclusion, please login ...

Further abstracts you may be interested in

#804 The Plasma Chromogranin A Level Predicts Survival and Tumor Response in Patients with Gastroenteropancreatic Neuroendocrine Tumors
Introduction: The plasma chromogranin A (CgA) level is a reliable biomarker for identifying patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Conference: 11th Annual ENETS Conference (2014)
Category: Biomarkers
Presenting Author: M.D. Tsann-Long Hwang
Authors: Chou W C, Chen J S, Hsu J T, Chen T C, ...
#809 Serum Chromogranin A is a Predictor for Liver Metastatic Tumor Burden and Therapeutic Response in Advanced Non-Functional Pancreatic Neuroendocrine Tumors
Introduction: The relationship between CgA level and liver metastatic (LM) tumor burden as well as therapeutic response is not well-established.
Conference: 11th Annual ENETS Conference (2014)
Category: Biomarkers
Presenting Author: M.D. Xu Han
Authors: Zhang C, Han X, Tang M, Ji Y, ...
Keywords: CgA NF-PNETs LM
#832 The Role of Plasma Chromogranin A as Assessment of Treatment Response in Grade 1-3 Non-Functioning Gastroenteropancreatic (GEP) Neuroendocrine Tumors
Introduction: Chromogranin A (CgA) is considered to be of value not only in diagnosis but also in monitoring the disease response to treatment. However, only a few studies have been published on this issue.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Chemotherapy
Presenting Author: Professor Young Park
Authors: Park Y, Kim S, Lee J, Park S, ...
#2190 A Prospective Nordic Study on the Use of Chromogranin A for the Prediction of Progression in Patients with Pancreatic and Small Intestinal Neuroendocrine Tumors
Introduction: Retrospective studies showed that changes in plasma chromogranin A (CgA) might predict change in tumor burden in gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients.
Conference: 15th Annual ENETS conference (2018)
Category: Biomarkers
Presenting Author: Gitte Dam
Keywords: gep-net, ct, cga, correlation
#1497 Circulating Neuroendocrine Tumor Gene Signature, the NETest, Defines Therapy in GEP-NETs
Introduction: Early and precise delineation of therapeutic responses are key issues in GEP-NET management. Imaging has limitations in sensitivity while secretory biomarkers e.g., CgA is controversial.
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: Professor Mark Kidd
Keywords: NETest, CgA, PCR
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.